New Pill Significantly Boosts IVF Success Rates

Clinical trials reveal OXO-001 improves pregnancy and live birth outcomes in fertility treatments

OXO-001 increases ongoing pregnancy rates to 46.3% compared to 35.7% with placebo.
Live birth rates improved to 42.6% for women taking OXO-001 versus 35.7% for placebo group.
The drug acts directly on the womb lining, enhancing embryo implantation.
Phase three trials will include women using their own eggs to further validate results.
Common side effects include mild to moderate headaches, nausea, and dizziness.